| scholarly article | Q13442814 |
| P50 | author | Terrance Bellnier | Q89330800 |
| Geoffrey W Brown | Q89330805 | ||
| Tulio R Ortega | Q89330808 | ||
| P2860 | cites work | Long-term opioid management for chronic noncancer pain | Q24240811 |
| Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects | Q24606148 | ||
| The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | Q24643876 | ||
| Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies | Q26749305 | ||
| The biopsychosocial approach to chronic pain: Scientific advances and future directions | Q30463718 | ||
| Pharmacokinetics and pharmacodynamics of cannabinoids | Q34185013 | ||
| Cannabis in cancer care | Q34467418 | ||
| Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review | Q34481944 | ||
| CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. | Q34518212 | ||
| Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial | Q34575407 | ||
| Vaporization as a smokeless cannabis delivery system: a pilot study | Q34618398 | ||
| Emotional and neurobehavioural status in chronic pain patients | Q34640938 | ||
| Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010 | Q34664106 | ||
| Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial | Q34731928 | ||
| Cannabinoid analgesia | Q34786828 | ||
| The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. | Q50921699 | ||
| The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. | Q53474628 | ||
| [Pain epidemiology and health-related quality of life in patients with chronic non-malignant pain] | Q60445499 | ||
| Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy | Q68732551 | ||
| Cannabis effect on spasticity in spinal cord injury | Q72107147 | ||
| Pain assessment and treatment in the managed care environment. A position statement from the American Pain Society | Q77905757 | ||
| Synergistic interactions between cannabinoid and opioid analgesics | Q35620905 | ||
| Trends in long-term opioid therapy for chronic non-cancer pain | Q35758775 | ||
| Substance use disorders in a primary care sample receiving daily opioid therapy | Q35962711 | ||
| Amygdala pain mechanisms | Q36430485 | ||
| Amygdala activity contributes to the dissociative effect of cannabis on pain perception | Q36546986 | ||
| Low-dose vaporized cannabis significantly improves neuropathic pain | Q36593518 | ||
| Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective | Q37065797 | ||
| A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain | Q37141496 | ||
| Opioid use behaviors, mental health and pain--development of a typology of chronic pain patients. | Q37276433 | ||
| Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa | Q38219750 | ||
| The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review | Q38337699 | ||
| Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials | Q38386497 | ||
| Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. | Q38690977 | ||
| The Role of Cannabinoid Receptors in the Descending Modulation of Pain | Q38974429 | ||
| The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study | Q39176501 | ||
| Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. | Q39192669 | ||
| A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. | Q39237599 | ||
| Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system | Q39847202 | ||
| Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulation | Q40680337 | ||
| The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report. | Q41178764 | ||
| Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. | Q44351867 | ||
| Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products | Q44669607 | ||
| The dimensions of pain quality: factor analysis of the Pain Quality Assessment Scale | Q45185276 | ||
| A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment | Q48131842 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | chronic pain | Q1088113 |
| P304 | page(s) | 110-115 | |
| P577 | publication date | 2018-04-26 | |
| P1433 | published in | The mental health clinician | Q60644342 |
| P1476 | title | Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis | |
| P478 | volume | 8 |
Search more.